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Abstract 
Introduction: The Bethesda classification system for reporting thyroid cytopathology is the standard for interpreting fine needle aspirate 
(FNA). Because of its heterogeneity and inconsistent reporting, atypia of undetermined significance or follicular lesion of undetermined 
significance (AUS/FLUS), known as Bethesda category III, is the most controversial category. Thyroid nodules that fall within Bethesda 
categories III–IV have an overall risk of malignancy of between 15 and 40%. The aim of this study was to determine the malignancy rate 
in Bethesda III nodules. 
material and methods: A retrospective study was performed for 1166 patients who underwent thyroid surgery for multinodular goitre 
(MNG) or solitary nodular goitre (SNG) in our institution between June 2010 and May 2020. Data retrieved included demographic char-
acteristics of the patients, FNB cytology, thyroid function test results, type of thyroidectomy, and final histology results.
results: During the study period, 29.5% (344/1166) of patients with an FNA categorized as AUS/FLUS underwent thyroid surgery. Of these 
344 patients, 190 were diagnosed with MNG and 154 with SNG. Incidental malignancy was found in 35 of 190 cases of MNG (18.42%) 
and 31 of 154 cases of SNG (20.13%). The most common malignant tumour type in either category was the follicular variant of papillary 
thyroid carcinoma.
conclusions: The current study demonstrates that patients with a FNA categorized as AUS/FLUS may have a higher risk of malignancy 
than traditionally believed. Reconsideration may be necessary to guidelines that recommend observation or repeat FNA in this category 
of patients. (Endokrynol Pol 2021; 72 (2): 143–144)
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Introduction
The incidence of thyroid cancer has increased dramati-
cally in the last few decades, and it is now the fastest 
growing cancer in females, with papillary thyroid 
carcinoma (PTC) accounting for the majority of cases 
[1]. However, thyroid lesions are often found on the 
thyroid gland, and the majority of these are not malig-
nancies. After an initial ultrasound (US), the next step 
in assessing the risk of cancer of a thyroid lesion is fine 
needle aspiration (FNA) [2]. The result of the biopsy 
can fall within one of six categories as defined by the 
Bethesda system for reporting FNA cytopathology re-
sults: I (non-diagnostic or unsatisfactory), II (benign), III 
(atypia of undetermined significance [AUS] or follicular 
lesion of undetermined significance [FUS]), IV (follicu-
lar neoplasm or suspicious for a follicular neoplasm), 
V (suspicious for malignancy), and VI (malignant) [3]. 
Because of its heterogeneity and inconsistent report-
ing, (AUS/FLUS), also known as Bethesda category III, 
is the most controversial category [4]. The aim of this 
study was to determine the malignancy rate in Bethesda 
III nodules in patients undergoing thyroidectomy for 
multinodular goitre (MNG) or solitary nodular goitre 
(SNG) in our institution.
Material and methods
Between June 2010 and May 2020, 344 out of 1166 patients who un-
derwent thyroid surgery for multinodular goitre (MNG) or solitary 
nodular goitre (SNG) in our institution had a FNA categorized as 
AUS/FLUS and were considered for this retrospective study. In-
formed consent or approval by the local ethics committee was not 
obtained due to the observational nature of the study. Data were 
collected from medical and operating theatre records as well as from 
the hospital-coded database. Statistical analyses were done using 
SPSS for Windows 8.0. Student’s t-test for normally distributed vari-
ables, Mann-Whitney U test for skewed variables, and chi-square 
test and Fisher ’s exact tests for comparison of results between 
groups. A p value < 0.05 was considered statistically significant.
Results
During the study period, 29.5% (344/1166) of patients 
with a FNA categorized as AUS/FLUS underwent thy-
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nodules that fall within Bethesda categories III and 
IV have an overall risk of malignancy of between 15 
and 40%. If Bethesda III or IV lesions are found to be 
malignant, the most common histological subtype is 
the follicular variant of papillary thyroid carcinoma. 
This variant is generally less aggressive than classic 
papillary thyroid carcinoma. Furthermore, this subtype 
has been shown to have a lower risk of lymph node 
metastases, recurrence, and local extension, especially 
if it is encapsulated [3].
A retrospective analysis showed that ultrasonogra-
phy (K-TIRADS 5) is the most influential independent 
predictor of malignancy in AUS/FLUS patients [5]. 
Another retrospective study showed that the rate of 
malignancy of 350 nodules with AUS/FLUS that went 
on to surgery was approximately 38%. They found that 
the most common malignancy was PTC (86.8%) [4].
Our study has several limitations because the 
patients were assessed retrospectively from a single 
centre. Our study indicates the need for a prospective 
randomized controlled trial of AUS/FLUS patients with 
MNG and SNG.
Conclusions
In conclusion, the current study demonstrates that pa-
tients with a FNA categorized as AUS/FLUS may have 
a higher risk of malignancy than traditionally believed. 
Reconsideration may be necessary to guidelines that 
recommend observation or repeat FNA in this category 
of patients.
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roid surgery in our institution. Of these 344 patients, 
190 were diagnosed with MNG and 154 with SNG. To-
tal thyroidectomy was performed in 15.1% (52/344) of 
the nodules with AUS/FLUS, subtotal thyroidectomy 
in 81.1% (279/344) of cases, and thyroid lobectomy in 
3.8% (13/344) of these patients. The demographic data 
of the patients with MNG and SNG are presented in 
Table 1. There were more female patients than male 
in both the MNG and SNG groups. The mean age 
of patients with MNG at the time of surgery was 
48.6 ± 11.18 years, with no significant difference 
compared with the patients with SNG, at 47.9 ± 12.35 
years. In addition, there was no significant difference 
regarding operation time, hospital stay, and rate of 
malignancy between the two groups. Incidental ma-
lignancy was found in 35 of 190 cases of MNG (18.42%) 
and in 31 of 154 cases of SNG (20.13%). The most com-
mon malignant tumour type in either category was the 
follicular variant of papillary thyroid carcinoma. There 
was no significant difference regarding histological 
subtypes of all other malignant tumours between the 
MNG and SNG groups.
Discussion 
The results of our study demonstrate that the rate of 
malignancy is 18.1% for AUS/FLUS patients with MNG 
and 20.1% for those with SNG, and the most com-
mon subtype is follicular variant of papillary thyroid 
carcinoma (PTC). According to the literature, thyroid 
table 1. Number of cases, gender, age, hospitalization, duration 
of surgery, and histological outcomes for the undetermined 
significance or follicular lesion of undetermined significance 
(AUS/FLUS) patients with multinodular goitre (MNG) and 
solitary nodular goitre (SNG). Values are presented as mean 
± standard deviation (SD) with percentage in parentheses
Variable MNG SNG p
Number of patients  
(n = 344) 190 (55) 154 (45)
Males/Females 
(67/277) 36/154 31/123 > 0.05*
Mean age (± SD) 
[yrs] 48.6 ± 11.18 47.9 ± 12.35 > 0.05
Hospitalization  
(± SD) [d] 4.3 ± 2.7 4.1 ± 2.9 > 0.05
Malignancies  
(n = 66) 35 (18.4) 31 (20.1) > 0.05
Mean operative  
(± SD) time [min] 103.1 ± 59.1 101.7 ± 47.4 > 0.05
*statistically significant (p < 0.05)
